TNBC vs non-TNBC: A retrospective review of differences in mean age, family history, smoking history, and stage at diagnosis

Clinical Advances in Hematology and Oncology

Volumn 12, Issue 6, 2014, Pages 377-381

  Tariq, Khurram ^a   Farhangi, Arezo ^b   Rana, Fauzia ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Division of Hematology and Medical Oncology ^*

Author keywords

Family history; Smoking; Triple negative breast cancer

Indexed keywords

ADULT; AGE; ARTICLE; CANCER REGISTRY; CANCER STAGING; ETHNICITY; FAMILY HISTORY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY; SMOKING; TRIPLE NEGATIVE BREAST CANCER; AGED; BREAST NEOPLASMS; ETHNIC GROUP; ETHNOLOGY; FAMILY; META ANALYSIS; MIDDLE AGED; PATHOLOGY; REGISTER; TRIPLE NEGATIVE BREAST NEOPLASMS; UNITED STATES;

ADULT; AGE FACTORS; AGED; BREAST NEOPLASMS; ETHNIC GROUPS; FAMILY; FEMALE; FLORIDA; HUMANS; MIDDLE AGED; NEOPLASM STAGING; REGISTRIES; RETROSPECTIVE STUDIES; SMOKING; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84902589481     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Parkin DM, Fernández LM. Use of statistics to assess the global burden of breast cancer. Breast J. 2006;12(1)(suppl 1):S70-S80.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
3. Anderson BO, Yip CH, Smith RA, et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer. 2008;113(8)(suppl):2221-2243.
4. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-236.
5. World Health Organization. National Cancer Control Programmers: Policies and Managerial Guidelines. 2nd ed. Geneva, Switzerland: World Health Organization; 2002.
6. Tavassoli FA, Devilee P, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC press; 2003.
7. de Ruijter TC, Veeck J, de Hoon JPJ, van Engeland M, Tjan-Heijnen VC. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. 2011;137(2):183-192.
8. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
9. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-10874.
10. Callagy G, Cattaneo E, Daigo Y, et al. Molecular classifcation of breast carcinomas using tissue microarrays. Diagn Mol Pathol. 2003;12(1):27-34.
11. Abd El-Rehim DM, Ball G, Pinder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifes biologically distinct classes of breast cancer confrming recent cDNA expression analyses. Int J Cancer. 2005;116(3):340-350.
12. Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer Control. 2010;17(3):173-176.
13. van'T Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530-536.
14. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418-8423.
15. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-3734.
16. Anders C, Carey LA. Understanding and treating triple-negative breast cancer. Oncology (Williston Park). 2008;22(11):1233-1239.
17. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275-1281.
18. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492-2502.
19. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 pt 1):4429-4434.
20. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28(7):1145-1153.
21. Kaplan HG, Malmgren JA. Impact of triple negative phenotype on breast cancer prognosis. Breast J. 2008;14(5):456-463.
22. Aleskandarany MA, Green AR, Benhasouna AA, et al. Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Res. 2012;14(1):R3.
23. Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast cancer in young women: poor survival despite intensive treatment. PLoS ONE. 2009;4(11):e7695.
24. Azim HA Jr, Michiels S, Bedard PL, et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profling. Clin Cancer Res. 2012;18(5):1341-1351.
25. Kim EK, Noh WC, Han W, Noh DY. Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study. World J Surg. 2011;35(6):1244-1253.
26. Menashe I, Anderson W F, Jatoi I, Rosenberg PS. Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis. J Natl Cancer Inst. 2009;101(14):993-1000.
27. Dignam JJ. Efficacy of systemic adjuvant therapy for breast cancer in African-American and Caucasian women. J Natl Cancer Inst Monogr. 2001;2001(30):36-43.
28. Ayanian JZ, Kohler BA, Abe T, Epstein AM. Te relation between health insurance coverage and clinical outcomes among women with breast cancer. N Engl J Med. 1993;329(5):326-331.
29. Bradley CJ, Given CW, Roberts C. Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst. 2002;94(7):490-496.
30. Jatoi I, Becher H, Leake CR. Widening disparity in survival between white and African-American patients with breast carcinoma treated in the U. S. Department of Defense healthcare system. Cancer. 2003;98(5):894-899.
31. McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ. 2000;321(7261):624-628.
32. Conway K, Edmiston SN, Cui L, et al. Prevalence and spectrum of p53 mutations associated with smoking in breast cancer. Cancer Res. 2002;62(7):1987-1995.
33. Yamasaki E, Ames BN. Concentration of mutagens from urine by absorption with the nonpolar resin XAD-2: cigarette smokers have mutagenic urine. Proc Natl Acad Sci U S A. 1977;74(8):3555-3559.
34. Shu HP, Bymun EN. Systemic excretion of benzo(a)pyrene in the control and microsomally induced rat: the infuence of plasma lipoproteins and albumin as carrier molecules. Cancer Res. 1983;43(2):485-490.
35. MacNicoll AD, Easty GC, Neville AM, Grover PL, Sims P. Metabolism and activation of carcinogenic polycyclic hydrocarbons by human mammary cells. Biochem Biophys Res Commun. 1980;95(4):1599-1606.
36. Faraglia B, Chen SY, Gammon MD, et al. Evaluation of 4-aminobiphenyl-DNA adducts in human breast cancer: the infuence of tobacco smoke. Carcinogenesis. 2003;24(4):719-725.
37. Firozi PF, Bondy ML, Sahin AA, et al. Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer. Carcinogenesis. 2002;23(2):301-306.
38. Perera FP, Estabrook A, Hewer A, et al. Carcinogen-DNA adducts in human breast tissue. Cancer Epidemiol Biomarkers Prev. 1995;4(3):233-238.
39. Conway K, Edmiston SN, Cui L, et al. Prevalence and spectrum of p53 mutations associated with smoking in breast cancer. Cancer Res. 2002;62(7):1987-1995.
40. Jensen J, Christiansen C, Rødbro P. Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause. N Engl J Med. 1985;313(16):973-975.
41. Jensen J, Christiansen C. Efects of smoking on serum lipoproteins and bone mineral content during postmenopausal hormone replacement therapy. Am J Obstet Gynecol. 1988;159(4):820-825.
42. Baron JA, La Vecchia C, Levi F. Te antiestrogenic efect of cigarette smoking in women. Am J Obstet Gynecol. 1990;162(2):502-514.
43. MacMahon B, Trichopoulos D, Cole P, Brown J. Cigarette smoking and urinary estrogens. N Engl J Med. 1982;307(17):1062-1065.
44. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med. 2001;344(4):276-285.
45. Terry PD, Rohan TE. Cigarette smoking and the risk of breast cancer in women: a review of the literature. Cancer Epidemiol Biomarkers Prev. 2002;11(10 pt 1):953-971.
46. Terry PD, Miller AB, Rohan TE. Cigarette smoking and breast cancer risk: a long latency period? Int J Cancer. 2002;100(6):723-728.
47. Olson JE, Vachon CM, Vierkant RA, et al. Prepregnancy exposure to cigarette smoking and subsequent risk of postmenopausal breast cancer. Mayo Clin Proc. 2005;80(11):1423-1428.
48. Li CI, Malone KE, Daling JR. Te relationship between various measures of cigarette smoking and risk of breast cancer among older women 65-79 years of age (United States). Cancer Causes Control. 2005;16(8):975-985.
49. Band PR, Le ND, Fang R, Deschamps M. Carcinogenic and endocrine disrupting efects of cigarette smoke and risk of breast cancer. Lancet. 2002;360(9339):1044-1049.
50. Gram IT, Braaten T, Terry PD, et al. Breast cancer risk among women who start smoking as teenagers. Cancer Epidemiol Biomarkers Prev. 2005;14(1):61-66.
51. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;358(9291):1389-1399.
52. Pharoah PD, Day NE, Dufy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer. 1997;71(5):800-809.
53. Lux MP, Fasching PA, Beckmann MW. Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med (Berl). 2006;84(1):16-28.
54. Pharoah PD, Day NE, Dufy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer. 1997;71(5):800-809.
55. Figueiredo JC, Ennis M, Knight JA, et al. Infuence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study. Breast Cancer Res Treat. 2007;105(1):69-80.
56. Margolin S, Johansson H, Rutqvist LE, Lindblom A, Fornander T. Family history, and impact on clinical presentation and prognosis, in a population-based breast cancer cohort from the Stockholm County. Fam Cancer. 2006;5(4):309-321.
57. McCaul KD, Branstetter AD, Schroeder DM, Glasgow RE. What is the relationship between breast cancer risk and mammography screening? A meta-analytic review. Health Psychol. 1996;15(6):423-429.
58. Cohen M. Breast cancer early detection, health beliefs, and cancer worries in randomly selected women with and without a family history of breast cancer. Psychooncology. 2006;15(10):873-883.
59. Gansler T, Henley SJ, Stein K, Nehl EJ, Smigal C, Slaughter E. Sociodemographic determinants of cancer treatment health literacy. Cancer. 2005;104(3):653-660.
60. Verkooijen HM, Chappuis PO, Rapiti E, et al. Impact of familial risk factors on management and survival of early-onset breast cancer: a population-based study. Br J Cancer. 2006;94(2):231-238.
61. Bouchardy C, Verkooijen HM, Fioretta G. Social class is an important and independent prognostic factor of breast cancer mortality. Int J Cancer. 2006;119(5):1145-1151.
62. Eerola H, Vahteristo P, Sarantaus L, et al. Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: a relative survival analysis from Finland. Int J Cancer. 2001;93(3):368-372.
63. Russo A, Herd-Smith A, Gestri D, et al. Does family history infuence survival in breast cancer cases? Int J Cancer. 2002;99(3):427-430.
64. Verkooijen HM, Chappuis PO, Rapiti E, et al. Impact of familial risk factors on management and survival of early-onset breast cancer: a population-based study. Br J Cancer. 2006;94(2):231-238.
65. Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol. 1999;17(11):3396-3402.
66. Jobsen JJ, Meerwaldt JH, van der Palen J. Family history in breast cancer is not a prognostic factor? Breast. 2000;9(2):83-87.
67. Vlastos G, Mirza NQ, Meric F, et al. Breast-conservation therapy in early-stage breast cancer patients with a positive family history. Ann Surg Oncol. 2002;9(9):912-919.
68. Veronesi A, de Giacomi C, Magri MD, et al. Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases. BMC Cancer. 2005;5(1):70.
69. Brekelmans C T, Tilanus-Linthorst MM, Seynaeve C, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer. 2007;43(5):867-876.
70. Rennert G, Bisland-Naggan S, Barnett-Griness O, et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. 2007;357(2):115-123.
71. Figueiredo JC, Ennis M, Knight JA, et al. Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study. Breast Cancer Res Treat. 2007;105(1):69-80.
72. Chappuis PO, Rosenblatt J, Foulkes WD. The influence of familial and hereditary factors on the prognosis of breast cancer. Ann Oncol. 1999;10(10):1163-1170.
73. Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute. SEER*Stat Database: Populations - Total U.S. (1969-2011). http://seer.cancer.gov/seerstat/. Accessed August 15, 2013.
74. Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med. 2003;163(1):49-56.